Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Redhill Biopharma Ltd reports successful RHB-102 Bioavailability clinical trial and planned submission of European Marketing Application in Q3/2014


Wednesday, 30 Apr 2014 07:02am EDT 

Redhill Biopharma Ltd:Reports positive results from comparative bioavailability study with RHB-102, a proprietary, extended-release, once-daily oral pill formulation of the anti-emetic oncology support drug ondansetron for prevention of chemotherapy and radiotherapy-induced nausea and vomiting.In light of the positive results from the bioavailability study and data from prior successful clinical studies conducted with RHB-102, and subject to various regulatory requirements.RedHill plans to submit, during the third quarter of 2014, a European MAA for RHB-102 with the UK as the reference EU member state for the European Mutual Recognition Procedure. 

Company Quote

588.1
6.2 +1.07%
31 Mar 2015